Support to help you on your treatment journey

Pay as little as $0* for Teva’s generic version of Forteo® (teriparatide injection)

*Offer covers commercially insured patients only.

Please note, this offer is not available for patients eligible for Medicare, Medicaid, or any other form of government insurance. Out-of-pocket costs may vary based on insurance coverage. Limitations apply. See full Terms and Conditions for eligibility restrictions.

Download Savings Card

Savings Program Terms and Conditions

Terms, Conditions, and Eligibility Requirements: Eligible patients must have commercial prescription insurance with coverage for Teva’s Teriparatide Injection, USP. Uninsured and cash-paying patients are NOT eligible for this Program. Patients enrolled in any state or federally funded healthcare program, including but not limited to, Medicare, Medigap, Medicaid, VA, DOD, TRICARE, Puerto Rico Government Health Insurance Plan, Medicare-eligible patients enrolled in an employer-sponsored health plan or prescription drug benefit program for retirees, are NOT eligible for this Program. Cash Discount Cards and other noninsurance plans are not valid as primary under this Program. This Program is restricted to residents of the United States and United States territories.

Patients may pay as little as $0 out of pocket for Teva’s Teriparatide Injection, USP. Maximum Program assistance per prescription and annual benefits apply and out-of-pocket expenses may vary. Patient is responsible for costs above maximum benefit amounts. This Program is not insurance. Void if copied, transferred, purchased, altered, or traded and where prohibited and restricted by law. The Program is not transferable. No substitutions are permitted. The Program form may not be sold, purchased, traded, or counterfeited. Void if reproduced. The Program benefit cannot be combined with any other financial assistance program, free trial, discount, prescription savings card, or other offer. This Program is managed by Mercalis on behalf of Teva Pharmaceuticals USA, Inc. Teva Pharmaceuticals USA, Inc. and its affiliates reserves the right to make eligibility determinations, to set Program benefit maximums, to monitor participation, and to change, rescind, revoke, or discontinue this Program at any time without notice. Limit one Program enrollment per individual. If you have any questions regarding this Program, your eligibility or benefits, or if you wish to discontinue your participation, please call 844-248-7949. Expiration Date: 12/31/2025.

The Copay Card is intended for the benefit of patients, not their insurance plans or other third parties. Patients whose commercial insurance plans do not apply Copay Card payments to satisfy patient out-of-pocket cost sharing amounts may not be eligible for the Copay Card. Similarly, patients whose commercial insurance plans require use of the Copay Card as a condition of the plan waiving some or all of otherwise applicable patient out-of-pocket cost sharing amounts may not be eligible for the Copay Card or have a reduced annual maximum program benefit. If you believe your commercial insurance plan may have such limitations, please call 844-248-7949.

Valid only for Teva’s Teriparatide Injection, USP, National Drug Code: 00093-1106-16

To the Patient: By redeeming this Program, you acknowledge that you are an Eligible Patient and you understand and agree to comply with the terms and conditions of this Program.

This Program is for eligible Commercially Insured Patients only. Patients may pay as little as $0 out of pocket for Teva’s Teriparatide Injection, USP. Maximum Program assistance per prescription and annual benefits apply and out-of-pocket expenses may vary. This Program must be presented along with your prescription for Teva’s Teriparatide Injection, USP and your primary insurance card to participate in this Program. Program not valid for Non-Insured/Cash-Paying Patients or where Teva’s Teriparatide Injection, USP is not covered by the primary insurance.

To the Pharmacist: When you apply this Program, you are certifying that Teva’s Teriparatide Injection, USP is being dispensed to an Eligible Patient in compliance with these terms and conditions and the Pharmacy has not submitted and will not submit a claim for reimbursement under any federal, state, or other governmental program for this prescription. For Commercially Insured Patients, please submit this claim to the primary Third-Party Payer first, then submit the balance due to Mercalis as a Secondary Payer COB (coordination of benefits) with patient responsibility and a valid Other Coverage Code (e.g., 08).

Reimbursement will be received from Mercalis. For questions regarding processing, please call the Help Desk at 844-248-7949.

Important Safety Information

What is the most important information I should know about Teriparatide Injection?

Possible bone cancer. During drug testing, the medicine in Teriparatide Injection caused some rats to develop a bone cancer called osteosarcoma. Studies in people have not shown that Teriparatide Injection increases your chance of getting osteosarcoma. There is little information about the chance of getting osteosarcoma in patients using Teriparatide Injection beyond 2 years.

Who should not use Teriparatide Injection?

Do not use Teriparatide injection if you:

are allergic to any of the ingredients in Teriparatide Injection. See the end of the Medication Guide for a complete list of the ingredients in Teriparatide Injection.

Symptoms of a serious allergic reaction of Teriparatide Injection may include swelling of the face, lips, tongue or throat that may cause difficulty in breathing or swallowing. Call your healthcare provider right away or get emergency medical help if you get any of these symptoms.

What should I tell my healthcare provider before using Teriparatide Injection?

Before you use Teriparatide Injection, tell your healthcare provider about all of your medical conditions, including if you:

have a certain bone disease called Paget’s disease or other bone disease.
have bone cancer or have had a history of bone cancer.
are a young adult whose bones are still growing.
have had radiation therapy.
are affected with a condition that runs in your family that can increase your chance of getting cancer in your bones.
have or have had too much calcium in your blood (hypercalcemia).
have or have had a skin condition with painful sores or wounds caused by too much calcium.
have or have had kidney stones.
take medicines that contain digoxin.
are pregnant or plan to become pregnant. It is not known if Teriparatide Injection will harm your unborn baby.
are breastfeeding or plan to breastfeed. It is not known if Teriparatide passes into your breastmilk. You should not breastfeed while taking Teriparatide Injection.

Tell your healthcare provider about all the medicines you take including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

What are the possible side effects of Teriparatide Injection?

Teriparatide Injection may cause serious side effects including:

See “What is the most important information I should know about Teriparatide Injection?”
Bone cancer (osteosarcoma): Tell your healthcare provider right away if you have pain in your bones, pain in any areas of your body that does not go away, or any new or unusual lumps or swelling under your skin that is tender to touch.
Increased calcium in your blood. Tell your healthcare provider if you have nausea, vomiting, constipation, low energy, or muscle weakness. These may be signs there is too much calcium in your blood.
Worsening of your kidney stones. If you have or have had kidney stones your healthcare provider may check the calcium levels in your urine while you use Teriparatide Injection to see if there is worsening of this condition.
Decrease in blood pressure when you change positions. Some people may feel dizzy, get a fast heartbeat, or feel light-headed right after the first few doses of Teriparatide Injection. This usually happens within 4 hours of taking Teriparatide Injection and goes away within a few hours. For the first few doses, give your injections of Teriparatide Injection in a place where you can sit or lie down right away if you get these symptoms. If your symptoms get worse or do not go away, contact your healthcare provider before you continue using Teriparatide Injection.

The most common side effects of Teriparatide Injection include pain, nausea, and joint aches. These are not all the possible side effects of Teriparatide Injection. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

What is Teriparatide Injection?

Teriparatide Injection is a prescription medicine used to:

treat postmenopausal women who have osteoporosis who are at high risk for having broken bones (fractures) or who cannot use other osteoporosis treatments. Teriparatide Injection can lessen the chance of broken bones (fractures) in the spine and other bones in postmenopausal women with osteoporosis.
increase the bone mass in men with primary or hypogonadal osteoporosis who are at high risk for having broken bones (fractures) or who cannot use other osteoporosis treatments.
treat both men and women with osteoporosis due to use of glucocorticoid medicines, such as prednisone, for several months, who are at high risk for having broken bones (fractures) or who cannot use other osteoporosis treatments.

It is not known if Teriparatide Injection is safe and effective in children. Teriparatide Injection should not be used in children and young adults whose bones are still growing.

Please read the Medication Guide in the full Prescribing Information.